Analysis of heart rate variability in children during high flow nasal cannula therapy

M. Perez-Zabalza, R. Hagmeijer, B. J. Thio, J. Bors, X. Hoppenbrouwer, A. Garde

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective: Heart rate variability (HRV) is a non-invasive measure of the interaction between the autonomic nervous system (ANS) and the cardiovascular system and an indicator of physiologic stress. HRV is proposed as an alternative biomarker to the effect of high flow nasal cannula (HFNC) therapy, a non-invasive ventilation mode, in children with severe respiratory disease. Approach: Seven children with severe acute respiratory disease were included in this pilot study. All of them received HFNC treatment. Standard physiological variables, such as heart rate (HR), breathing rate (BR) and blood oxygen saturation (SpO2) were analyzed during HFNC therapy. HRV, which includes the time domain parameters defined by the mean of RR intervals (avRR), the standard deviation of RR intervals (stdRR), the root mean square of differences between adjacent RR intervals (rmsSD), and the frequency domain parameters defined by spectral powers of low frequency (LF, 0.04 Hz-0.15 Hz) and high frequency (HF, 0.15 Hz-0.4 Hz) bands was also analysed during therapy. Main results: Only the time domain parameter rmsSD showed a significant increase (from 0.03 to 0.08 s, p < 0.05) between the middle and the end of the therapy. No significant changes were observed in HR, BR and SpO2 throughout the therapy. Of these three variables, only HR and BR showed a high and statistically significant positive correlation. Significance: HRV analysis seems to be a promising alternative biomarker to monitor the effect of HFNC therapy on children with severe respiratory disease.

Original languageEnglish
Article number045028
JournalBiomedical Physics and Engineering Express
Volume5
Issue number4
DOIs
Publication statusPublished - 11 Jul 2019

Fingerprint

Heart Rate
Respiration
Therapeutics
Biomarkers
Noninvasive Ventilation
Autonomic Nervous System
Acute Disease
Cardiovascular System
Cannula
Oxygen

Keywords

  • children
  • heart rate variability
  • high-flow therapy
  • severe respiratory disease

Cite this

@article{0241b259023543729e2e3bf06f1a4d8f,
title = "Analysis of heart rate variability in children during high flow nasal cannula therapy",
abstract = "Objective: Heart rate variability (HRV) is a non-invasive measure of the interaction between the autonomic nervous system (ANS) and the cardiovascular system and an indicator of physiologic stress. HRV is proposed as an alternative biomarker to the effect of high flow nasal cannula (HFNC) therapy, a non-invasive ventilation mode, in children with severe respiratory disease. Approach: Seven children with severe acute respiratory disease were included in this pilot study. All of them received HFNC treatment. Standard physiological variables, such as heart rate (HR), breathing rate (BR) and blood oxygen saturation (SpO2) were analyzed during HFNC therapy. HRV, which includes the time domain parameters defined by the mean of RR intervals (avRR), the standard deviation of RR intervals (stdRR), the root mean square of differences between adjacent RR intervals (rmsSD), and the frequency domain parameters defined by spectral powers of low frequency (LF, 0.04 Hz-0.15 Hz) and high frequency (HF, 0.15 Hz-0.4 Hz) bands was also analysed during therapy. Main results: Only the time domain parameter rmsSD showed a significant increase (from 0.03 to 0.08 s, p < 0.05) between the middle and the end of the therapy. No significant changes were observed in HR, BR and SpO2 throughout the therapy. Of these three variables, only HR and BR showed a high and statistically significant positive correlation. Significance: HRV analysis seems to be a promising alternative biomarker to monitor the effect of HFNC therapy on children with severe respiratory disease.",
keywords = "children, heart rate variability, high-flow therapy, severe respiratory disease",
author = "M. Perez-Zabalza and R. Hagmeijer and Thio, {B. J.} and J. Bors and X. Hoppenbrouwer and A. Garde",
year = "2019",
month = "7",
day = "11",
doi = "10.1088/2057-1976/ab2d11",
language = "English",
volume = "5",
journal = "Biomedical Physics and Engineering Express",
issn = "2057-1976",
publisher = "IOP Publishing Ltd.",
number = "4",

}

Analysis of heart rate variability in children during high flow nasal cannula therapy. / Perez-Zabalza, M.; Hagmeijer, R.; Thio, B. J.; Bors, J.; Hoppenbrouwer, X.; Garde, A.

In: Biomedical Physics and Engineering Express, Vol. 5, No. 4, 045028, 11.07.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Analysis of heart rate variability in children during high flow nasal cannula therapy

AU - Perez-Zabalza, M.

AU - Hagmeijer, R.

AU - Thio, B. J.

AU - Bors, J.

AU - Hoppenbrouwer, X.

AU - Garde, A.

PY - 2019/7/11

Y1 - 2019/7/11

N2 - Objective: Heart rate variability (HRV) is a non-invasive measure of the interaction between the autonomic nervous system (ANS) and the cardiovascular system and an indicator of physiologic stress. HRV is proposed as an alternative biomarker to the effect of high flow nasal cannula (HFNC) therapy, a non-invasive ventilation mode, in children with severe respiratory disease. Approach: Seven children with severe acute respiratory disease were included in this pilot study. All of them received HFNC treatment. Standard physiological variables, such as heart rate (HR), breathing rate (BR) and blood oxygen saturation (SpO2) were analyzed during HFNC therapy. HRV, which includes the time domain parameters defined by the mean of RR intervals (avRR), the standard deviation of RR intervals (stdRR), the root mean square of differences between adjacent RR intervals (rmsSD), and the frequency domain parameters defined by spectral powers of low frequency (LF, 0.04 Hz-0.15 Hz) and high frequency (HF, 0.15 Hz-0.4 Hz) bands was also analysed during therapy. Main results: Only the time domain parameter rmsSD showed a significant increase (from 0.03 to 0.08 s, p < 0.05) between the middle and the end of the therapy. No significant changes were observed in HR, BR and SpO2 throughout the therapy. Of these three variables, only HR and BR showed a high and statistically significant positive correlation. Significance: HRV analysis seems to be a promising alternative biomarker to monitor the effect of HFNC therapy on children with severe respiratory disease.

AB - Objective: Heart rate variability (HRV) is a non-invasive measure of the interaction between the autonomic nervous system (ANS) and the cardiovascular system and an indicator of physiologic stress. HRV is proposed as an alternative biomarker to the effect of high flow nasal cannula (HFNC) therapy, a non-invasive ventilation mode, in children with severe respiratory disease. Approach: Seven children with severe acute respiratory disease were included in this pilot study. All of them received HFNC treatment. Standard physiological variables, such as heart rate (HR), breathing rate (BR) and blood oxygen saturation (SpO2) were analyzed during HFNC therapy. HRV, which includes the time domain parameters defined by the mean of RR intervals (avRR), the standard deviation of RR intervals (stdRR), the root mean square of differences between adjacent RR intervals (rmsSD), and the frequency domain parameters defined by spectral powers of low frequency (LF, 0.04 Hz-0.15 Hz) and high frequency (HF, 0.15 Hz-0.4 Hz) bands was also analysed during therapy. Main results: Only the time domain parameter rmsSD showed a significant increase (from 0.03 to 0.08 s, p < 0.05) between the middle and the end of the therapy. No significant changes were observed in HR, BR and SpO2 throughout the therapy. Of these three variables, only HR and BR showed a high and statistically significant positive correlation. Significance: HRV analysis seems to be a promising alternative biomarker to monitor the effect of HFNC therapy on children with severe respiratory disease.

KW - children

KW - heart rate variability

KW - high-flow therapy

KW - severe respiratory disease

U2 - 10.1088/2057-1976/ab2d11

DO - 10.1088/2057-1976/ab2d11

M3 - Article

VL - 5

JO - Biomedical Physics and Engineering Express

JF - Biomedical Physics and Engineering Express

SN - 2057-1976

IS - 4

M1 - 045028

ER -